NO20024679D0 - Crystalline Pharmaceuticals - Google Patents

Crystalline Pharmaceuticals

Info

Publication number
NO20024679D0
NO20024679D0 NO20024679A NO20024679A NO20024679D0 NO 20024679 D0 NO20024679 D0 NO 20024679D0 NO 20024679 A NO20024679 A NO 20024679A NO 20024679 A NO20024679 A NO 20024679A NO 20024679 D0 NO20024679 D0 NO 20024679D0
Authority
NO
Norway
Prior art keywords
pharmaceuticals
crystalline
crystalline pharmaceuticals
lopinavir
disclosed
Prior art date
Application number
NO20024679A
Other languages
Norwegian (no)
Other versions
NO20024679L (en
NO325005B1 (en
Inventor
Daniel A Dickman
Sanjay Chemburkar
James J Fort
Rodger F Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024679(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20024679D0 publication Critical patent/NO20024679D0/en
Publication of NO20024679L publication Critical patent/NO20024679L/en
Publication of NO325005B1 publication Critical patent/NO325005B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

New crystalline forms of lopinavir are disclosed.
NO20024679A 2000-03-30 2002-09-30 Crystalline forms of lopinavir, pharmaceutical compositions comprising these and their use NO325005B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (3)

Publication Number Publication Date
NO20024679D0 true NO20024679D0 (en) 2002-09-30
NO20024679L NO20024679L (en) 2002-09-30
NO325005B1 NO325005B1 (en) 2008-01-14

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024679A NO325005B1 (en) 2000-03-30 2002-09-30 Crystalline forms of lopinavir, pharmaceutical compositions comprising these and their use

Country Status (22)

Country Link
EP (1) EP1268442A2 (en)
JP (1) JP2003529592A (en)
KR (1) KR100773258B1 (en)
CN (2) CN1330639C (en)
AR (2) AR033360A1 (en)
AU (3) AU5092001A (en)
BG (1) BG107165A (en)
BR (1) BR0109433A (en)
CA (1) CA2403635A1 (en)
CZ (1) CZ20023529A3 (en)
HU (1) HUP0302675A3 (en)
IL (1) IL151551A0 (en)
MX (1) MXPA02009559A (en)
MY (1) MY128296A (en)
NO (1) NO325005B1 (en)
NZ (1) NZ521183A (en)
PE (1) PE20011232A1 (en)
PL (1) PL359727A1 (en)
SA (2) SA01220270B1 (en)
SK (1) SK14832002A3 (en)
TW (1) TWI284640B (en)
WO (1) WO2001074787A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN112830899A (en) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 Novel lopinavir crystal form and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
HUP0302675A2 (en) 2003-12-29
AU2001250920B2 (en) 2006-06-29
AU2006222711A1 (en) 2006-10-19
AU5092001A (en) 2001-10-15
PE20011232A1 (en) 2001-12-08
CN1330639C (en) 2007-08-08
HUP0302675A3 (en) 2004-03-29
SA01220270B1 (en) 2006-11-14
NO20024679L (en) 2002-09-30
MXPA02009559A (en) 2003-05-21
KR100773258B1 (en) 2007-11-05
TWI284640B (en) 2007-08-01
WO2001074787A2 (en) 2001-10-11
AR049560A2 (en) 2006-08-16
CN1422259A (en) 2003-06-04
KR20030011807A (en) 2003-02-11
CZ20023529A3 (en) 2003-02-12
NO325005B1 (en) 2008-01-14
CN101066952A (en) 2007-11-07
WO2001074787A3 (en) 2002-02-07
IL151551A0 (en) 2003-04-10
SK14832002A3 (en) 2003-02-04
MY128296A (en) 2007-01-31
PL359727A1 (en) 2004-09-06
CA2403635A1 (en) 2001-10-11
EP1268442A2 (en) 2003-01-02
NZ521183A (en) 2004-03-26
JP2003529592A (en) 2003-10-07
SA06270303B1 (en) 2009-08-02
BR0109433A (en) 2004-08-10
AR033360A1 (en) 2003-12-17
BG107165A (en) 2003-07-31

Similar Documents

Publication Publication Date Title
EA199900373A2 (en) PHARMACEUTICAL COMPOSITIONS
DOP2001000151A (en) IMIDAZOPIRIMIDINE DERIVATIVES AND TRIAZOLOPIMIDINE DERIVATIVES.
MA26812A1 (en) PYRIMIDINE-2,4,6-TRIONES INHIBITORS OF METALLOPROTEINASES
SE0000540D0 (en) New compounds
IT1319645B1 (en) CRYSTALLINE BASE OF CITALOPRAM.
NO20034439L (en) benzamidine derivatives
NO20043067L (en) Dynamic presence management
NO20003967D0 (en) Pharmaceuticals
DK3808743T3 (en) HIV-inhibiting pyrimidine derivatives
NO20034045D0 (en) Metalloproteinases inhibitors
DE60230216D1 (en) Kasko Think tablets amplifier
NO20044597L (en) Chemical connections
NO20034032D0 (en) Metalloproteinases inhibitors
NO20033679D0 (en) New pyrimidine compounds
SE9901077D0 (en) Novel use
SE0103710D0 (en) Compounds
SE9801494D0 (en) Novel use
BR0007922A (en) Calcilic compounds
DK1331972T3 (en) Pharmaceuticals
NO20015892L (en) Inhibitors of metal proteinases
NO20024679D0 (en) Crystalline Pharmaceuticals
ATE343390T1 (en) CALCILYTIC COMPOUNDS
DK1177191T3 (en) Substituted benzimidazoles, preparation and use thereof as agents for the control of parasitic protozoa
IT1320031B1 (en) ARRANGEMENT OF NETWORKS.
DE60232650D1 (en) PEPTIDDEFORMYLASEINHIBITOREN

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application